Conquering COVID Part 2.4 (aka the 15th Installment in a Finite Series):
“Phase 3 Vaccine Trials are becoming ubiquitous-Time to Score A Touchdown?!” (aka field goals are fine, but touchdowns are better)
November 3, 2020

by Mark A. Moyad, MD, MPH

“I am concerned, of course, but I am also incredibly optimistic.”
(Note: All references are at the end of the column-thank you.)

First, I want to apologize. I am sorry. I was on a fabulous roll and wrote countless pages of COVID-19 updates from March to September and then, for many weeks/months almost nothing, except the sound of crickets. Why have I been silent for the last month or so? Good question. September is Prostate Cancer Awareness Month and October is Breast Cancer Awareness Month. I have a multitude of other good excuses (a "dog ate my homework" kind of thing), but I am back and feeling stronger and more energized than ever, my friends, and through all of this I only rely on “1,3,7-trimethylxanthine” (aka “caffeine”) to keep me awake! Why am I so excited? It is because the ball is now on the two yard line and it is time to punch it in for a touchdown! Yes, time to score because we now have Phase 3 trials everywhere! I do not want a field goal, but a touchdown! Again, I want a touchdown!

I am so greedy for a touchdown because of a plethora (nice SAT word) of Phase 3 trials going on with vaccines and other medications. Phase 3 trials are ubiquitous? Yes! Phase 3 means you are now one step away from demonstrating enough potential data to be approved for widespread utilization. How in the “H-E-double-toothpicks” did the research go from laboratory studies to human Phase 1 and 2, and now Phase 3 within 6 months, and then hopefully and potentially emergency use authorization (EUA) or simply FDA approval? Can you imagine that pace with a cancer prevention or treatment medicine? Countless researchers around the world have been doing their thing since the pandemic started. So, now the ball has been moved from one side of the field to the other, and it is time to score a touchdown, and not a field goal. I wish Michigan football could do that more often (sorry, I needed that personal moment of therapy after this past weekend). Look, a field goal would be nice, but we should score a touchdown! Why? Buckle up, because here we go, and we are going to focus on the bottom line. Here comes a wonderful fact - there are over 150+ vaccines being studied around the globe and nine are now in the final stages (aka moving to, or already in, PHASE 3). So, let us start by reviewing just the two phase 3 clinical trials that are likely to report their initial results in 2020 or in early 2021. My hope is that both of these companies are able to report initial news in 2020. The first company is Moderna (I know the first two letters you have to love…"Mo" as in “Moyad”), and the second company is Pfizer, working with another company from Europe known as “BioNTech.”I decided to address some of the most common questions I have been asked in the following:

The Two Phase-3 COVID-19 Vaccine Clinical Trials Likely to First Report Results in 2020 or Early 2021

Is this company currently in a Phase-3 COVID-19 vaccine trial?
Moderna: Heck Yes! Called the “COVE” (Coronavirus Efficacy) Study. Pfizer/BioNTech: Heck Yes! Just called the Pfizer/BioNTech study.

When was the Phase-3 start date?
Moderna: July 27, 2020 (approximately)
Pfizer/BioNTech: July 27, 2020 (approximately)

What kind of vaccine is it? (note: the approach or “platform” is similar between the two companies and there is absolutely no live virus utilized in the vaccine itself).
Moderna: Known officially as “mRNA-1273” where a genetic blueprint or script of a protein part of COVID-19 is provided to humans to ultimately produce or trigger an immune memory and response to the real virus in the future.
Pfizer/BioNTech: Also, an mRNA vaccine, but known officially as “BNT162b2”. BNT162b2-a nucleoside-modified messenger RNA (mRNA) candidate, which means the vaccine harbors a small amount of the script of COVID-19, which also allows body to go after the real virus in the future.

How many people are they recruiting?
Moderna: 30,000
Pfizer/BioNTech: 44,000 (study initial goal was 30,000 participants and then was expanded to 44,000 to increase diversity of participants).

How many people have they recruited up to now?
Moderna: 30,000! Study is fully recruited (more than 25,000 have received both doses)! Approximately 37% of participants are “minorities/have diverse backgrounds” (20% Hispanic/Latinx, 10% Black/AA, 4% Asian, 3% other); 25% of the participants are the age of 65 or older.
Pfizer/BioNTech: Almost 44,000 Study is almost fully recruited-actually 43,249 participants on 11/2/20! (more than 37,000 have received both doses)! Approximately 43% of participants overall or globally (30% in the U.S. trials) are “minorities/have diverse backgrounds” (26% Hispanic/Latinx, 10% Black/AA, 5% Asian, 0.7% Native American); 41% ages 56 to 85 years old.

How many doses or injections do you need?
Moderna: 2-doses or 2-total injections needed and each single injection or dose is separated by a total of 28-days. The placebo arm of this study will receive saline injections.
Pfizer/BioNTech: 2-doses or 2-total injections needed and each single injection or dose is separated by a total of 21-days. The placebo arm of this study will receive saline injections.

What is/are the catches?
Moderna: Vaccine needs to be transported/distributed and stored at a very cold temperature of -20 Celsius (-4 Fahrenheit), and once thawed it can be kept in a refrigerator for 7 days.
Pfizer/BioNTech: Vaccine needs to be transported/distributed and stored at a very cold temperature of -70 Celsius (-94 Fahrenheit) and once thawed it can be kept in a refrigerator for 24 hours or 2 hours at room temperature. The company is working on a way to increase refrigerator time of 7-10 days.

Why is the glass half full already?
Moderna: The independent data/safety monitoring committee has not stopped the trial, so safety has not been a major issue so far.
Pfizer/BioNTech: The independent data/safety monitoring committee has not stopped the trial, so safety has not been a major issue so far.
Extra Credit - Can You Tell Me More?
We all know the company Pfizer, yes? They were the ones that brought us drugs such as Viagra and Lipitor… anyway, they decided to team up with the German biotech company known as “BioNTech” in order to hopefully bring a COVID-19 vaccine to the public. The goal was to enroll 30,000 participants initially, and now the study has been expanded to enroll 44,000 people, so that adolescents as young as age 16 and people living with conditions such as Hepatitis B, C, and HIV can also participate. Wow! Again, there are two injections with this vaccine, and after you receive the first dose you are supposed to receive the second dose approximately 21 days later. Pfizer actually released their 137-page Phase-3 clinical trial protocol to the public in September.

Moderna is globally headquartered in Cambridge, MA and they also released their full 135-page Phase-3 clinical trial protocol online. A link to both of these Phase-3 protocols can be found in the reference section at the end of this column. It is interesting that the dosage being given in these two vaccine trials are in micrograms, or millionths of a gram, or one thousandth of a milligram, suggesting how little a dose it takes to develop a potential immune response to this virus. In fact, as I was writing this column, Pfizer announced that participants as young as 12-years old are now able to participate.

Moderna co-developed their vaccine with the National Institute of Allergy and Infectious Diseases (NIAID - part of the National Institutes of Health or NIH), and it is being tested at approximately 89 clinical trial sites in the U.S. Pfizer is testing their vaccine at approximately 150 clinical sites in six countries including: Argentina, Brazil, Germany, South Africa, Turkey and in 39 states in the U.S. It is possible that the independent data/safety group could report results any day or week, so I have my test tubes crossed on this one, as well as the Moderna vaccine. Okay, so now you know the deal, which is some of the results from both companies should be released soon in 2020 or early in 2021. Both companies are using a similar approach (mRNA), which suggests if one is helpful then the other one could be helpful, and of course then the antithesis of this statement is also true. Regardless, what if we do not get that touchdown? The test tube is half-full on this because there are many other Phase-3 clinical trials going on right now and all of them should report in 2021 (or hopefully sooner), and in the next issue of this column we will cover the similarities and differences between them.

So, you might be thinking the following: What would be tantamount to a COVID-19 vaccine field goal here? Well, arguably it would be a vaccine that passes the minimum threshold of efficacy (about 50% reduction), but again I want 7 points (much larger reductions than that).

Thank you for reading my latest installment and I wish you and your family the best of health. I am concerned, of course, but I am also incredibly optimistic! I look forward to modern day science and you of course, kicking COVID-19 and cancer in the gluteus maximus!

All of my best always,

Mark A. Moyad MD, MPH

PS. Some of the references I used in this column to help me learn something new:

Moderna Phase 3 Vaccine Protocol and Updates Can be Found at:

Pfizer Phase 3 (Also Phase 1 & 2) Vaccine Protocol Can be Found at:

Pfizer Phase 3 COVID-19 Clinical Trial Updates Can be Found at:

NIH News Release:

Please pay attention to all of the CDC recommendations that can be found at

Read my previous COVID-19 articles at:


Visit the Us TOO COVID page at: